Gene · 3702
Papers2,789
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
841 to 860 of 2,789
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Follicular lymphoma and macrophages: impact of approved and novel therapies. | Blood Adv | 2021 | 34570196 | PubTator, text mining | PubMed |
| The Tec Kinase Itk Integrates Naïve T Cell Migration and In Vivo Homeostasis. | Front Immunol | 2021 | 34566971 | PubTator, text mining | PubMed |
| Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real-world study. | Cancer Med | 2021 | 34558211 | PubTator, text mining | PubMed |
| Editorial: Beyond Histocompatibility - Understanding the Non-MHC Determinants Shaping Transplantation Outcome and Tolerance Induction. | Front Immunol | 2021 | 34557204 | PubTator, text mining | PubMed |
| Growth factor signaling predicts therapy resistance mechanisms and defines neuroblastoma subtypes. | Oncogene | 2021 | 34556815 | PubTator, text mining | PubMed |
| Cyclosporin A: A Repurposable Drug in the Treatment of COVID-19? | Front Med (Lausanne) | 2021 | 34552938 | PubTator, text mining | PubMed |
| Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non-Hodgkin Lymphoma. | Clin Cancer Res | 2021 | 34551904 | PubTator, text mining | PubMed |
| Target modulation and pharmacokinetics/pharmacodynamics translation of the BTK inhibitor poseltinib for model-informed phase II dose selection. | Sci Rep | 2021 | 34548595 | PubTator, text mining | PubMed |
| Case Report: EBV Chronic Infection and Lymphoproliferation in Four APDS Patients: The Challenge of Proper Characterization, Therapy, and Follow-Up. | Front Pediatr | 2021 | 34540765 | PubTator, text mining | PubMed |
| Repurposing of gastric cancer drugs against COVID-19. | Comput Biol Med | 2021 | 34537409 | PubTator, text mining | PubMed |
| Analysis of the polarization states of the alveolar macrophages in chronic obstructive pulmonary disease samples based on miRNA-mRNA network signatures. | Ann Transl Med | 2021 | 34532470 | PubTator, text mining | PubMed |
| Harnessing Treg Homeostasis to Optimize Posttransplant Immunity: Current Concepts and Future Perspectives. | Front Immunol | 2021 | 34526990 | PubTator, text mining | PubMed |
| An Immune-Associated Genomic Signature Effectively Predicts Pathologic Complete Response to Neoadjuvant Paclitaxel and Anthracycline-Based Chemotherapy in Breast Cancer. | Front Immunol | 2021 | 34526986 | PubTator, text mining | PubMed |
| Bortezomib enhances the anti-cancer effect of the novel Bruton's tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK. | Aging (Albany NY) | 2021 | 34508613 | PubTator, text mining | PubMed |
| CML derived exosomes promote tumor favorable functional performance in T cells. | BMC Cancer | 2021 | 34493241 | PubTator, text mining | PubMed |
| Genomics and metabolomics of early-stage thioacetamide-induced liver injury: An interspecies study between guinea pig and rat. | Toxicol Appl Pharmacol | 2021 | 34492290 | PubTator, text mining | PubMed |
| Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets - Beyond B Lymphocytes. | Front Cell Dev Biol | 2021 | 34485307 | PubTator, text mining | PubMed |
| Bruton's Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis. | Immunotargets Ther | 2021 | 34485183 | PubTator, text mining | PubMed |
| Hallmarks of Cancers: Primary Antibody Deficiency Versus Other Inborn Errors of Immunity. | Front Immunol | 2021 | 34484227 | PubTator, text mining | PubMed |
| Genome-Wide DNA Methylation Pattern in Whole Blood Associated With Primary Intracerebral Hemorrhage. | Front Immunol | 2021 | 34484198 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3702/papers?page=43